{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T12:51:52Z","timestamp":1767703912890,"version":"3.37.3"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2023,12,9]],"date-time":"2023-12-09T00:00:00Z","timestamp":1702080000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,12,9]],"date-time":"2023-12-09T00:00:00Z","timestamp":1702080000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Zambon"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1007\/s12325-023-02736-2","type":"journal-article","created":{"date-parts":[[2023,12,9]],"date-time":"2023-12-09T06:01:41Z","timestamp":1702101701000},"page":"638-648","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["The Effects of Safinamide in Chinese and Non-Chinese Patients with Parkinson\u2019s Disease"],"prefix":"10.1007","volume":"41","clinical-trial-number":[{"clinical-trial-number":"nct00627640","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03881371","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-7810-4514","authenticated-orcid":false,"given":"Carlo","family":"Cattaneo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4870-1431","authenticated-orcid":false,"given":"Jaime","family":"Kulisevsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,12,9]]},"reference":[{"key":"2736_CR1","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1136\/jnnp.2007.131045","volume":"79","author":"J Jankovic","year":"2008","unstructured":"Jankovic J. Parkinson\u2019s disease: clinical features and diagnosis. J Neurol Neurosurg Psychiatry. 2008;79:368\u201376.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"5","key":"2736_CR2","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/S1474-4422(09)70068-7","volume":"8","author":"KR Chaudhuri","year":"2009","unstructured":"Chaudhuri KR, Shapira AHV. Non-motor symptoms of Parkinson\u2019s disease: dopaminergic pathophysiology and treatment. Lancet Neurol. 2009;8(5):464\u201374.","journal-title":"Lancet Neurol"},{"key":"2736_CR3","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1007\/BF03033378","volume":"5","author":"TN Chase","year":"2003","unstructured":"Chase TN, Bibbiani F, Oh JD. Striatal glutamatergic mechanisms and extrapyramidal movement disorders. Neurotox Res. 2003;5:139\u201346.","journal-title":"Neurotox Res"},{"key":"2736_CR4","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1212\/01.wnl.0000247740.47667.03","volume":"68","author":"ER Dorsey","year":"2007","unstructured":"Dorsey ER, Constantinescu R, Thompson JP, et al. Projected number of people with Parkinson\u2019s disease in the most populous nations, 2005 through 2030. Neurology. 2007;68:384\u20136.","journal-title":"Neurology"},{"key":"2736_CR5","doi-asserted-by":"publisher","first-page":"17013","DOI":"10.1038\/nrdp.2017.13","volume":"3","author":"W Poewe","year":"2017","unstructured":"Poewe W, Seppi K, Tanner CM, et al. Parkinson disease. Nat Rev Dis Primers. 2017;3:17013. https:\/\/doi.org\/10.1038\/nrdp.2017.13.","journal-title":"Nat Rev Dis Primers"},{"key":"2736_CR6","doi-asserted-by":"publisher","first-page":"281","DOI":"10.3233\/JPD-129002","volume":"2","author":"AQ Rana","year":"2012","unstructured":"Rana AQ, Athar A, Owlia A, et al. Impact of ethnicity on non-motor symptoms of Parkinson\u2019s disease. J Parkinsons Dis. 2012;2:281\u20135.","journal-title":"J Parkinsons Dis"},{"key":"2736_CR7","doi-asserted-by":"publisher","first-page":"929","DOI":"10.3109\/00207454.2014.986573","volume":"125","author":"HJ Li","year":"2015","unstructured":"Li HJ, Zhang MF, Chen MX, et al. Validation of the nonmotor symptoms questionnaire for Parkinson\u2019s disease: results from a Chinese pilot study. Int J Neurosci. 2015;125:929\u201335.","journal-title":"Int J Neurosci"},{"key":"2736_CR8","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1007\/s00702-022-02465-w","volume":"129","author":"WH Jost","year":"2022","unstructured":"Jost WH. A critical appraisal of MAO-B inhibitors in the treatment of Parkinson\u2019s disease. J Neural Transm. 2022;129:723\u201336.","journal-title":"J Neural Transm"},{"issue":"7","key":"2736_CR9","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1517\/13543784.17.7.1115","volume":"17","author":"M Onofrj","year":"2007","unstructured":"Onofrj M, Bonanni L, Thomas A. An expert opinion on safinamide in Parkinson\u2019s disease. Expert Opin Investig Drugs. 2007;17(7):1115\u201325.","journal-title":"Expert Opin Investig Drugs"},{"issue":"2","key":"2736_CR10","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1002\/mds.25751","volume":"29","author":"R Borgohain","year":"2014","unstructured":"Borgohain R, Szasz J, Stanzione P, et al. Randomized trial of safinamide add-on to levodopa in Parkinson\u2019s disease with motor fluctuations. Mov Disord. 2014;29(2):229\u201337.","journal-title":"Mov Disord"},{"issue":"10","key":"2736_CR11","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1002\/mds.25961","volume":"29","author":"R Borgohain","year":"2014","unstructured":"Borgohain R, Szasz J, Stanzione P, et al. Two-year, randomized, controlled study of safinamide as add-on to levodopa in mid to late Parkinson\u2019s disease. Mov Disord. 2014;29(10):1273\u201380.","journal-title":"Mov Disord"},{"key":"2736_CR12","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1001\/jamaneurol.2016.4467","volume":"74","author":"AHV Schapira","year":"2017","unstructured":"Schapira AHV, Fox SH, Hauser RA, et al. Assessment of safety and efficacy of safinamide as a levodopa adjunct in patients with Parkinson\u2019s disease and motor fluctuations: a randomized clinical trial. JAMA Neurol. 2017;74:216\u201324.","journal-title":"JAMA Neurol"},{"key":"2736_CR13","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.parkreldis.2020.04.012","volume":"75","author":"N Hattori","year":"2020","unstructured":"Hattori N, Tsuboi Y, Yamamoto A, Sasagawa Y, Nomoto M. Efficacy and safety of safinamide as an add-on therapy to L-dopa for patients with Parkinson\u2019s disease: a randomized, double-blind, placebo-controlled, phase\u00a0II\/III study. Parkinsonism Relat Disord. 2020;75:17\u201323.","journal-title":"Parkinsonism Relat Disord"},{"issue":"11","key":"2736_CR14","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1007\/s40263-022-00958-6","volume":"36","author":"Q Wei","year":"2022","unstructured":"Wei Q, Tan Y, Xu P, et al. The XINDI study: a randomized phase\u00a0III clinical trial evaluating the efficacy and safety of safinamide as add-on therapy to levodopa in Chinese Parkinson\u2019s disease patients with motor fluctuations. CNS Drugs. 2022;36(11):1217\u201327.","journal-title":"CNS Drugs"},{"issue":"1","key":"2736_CR15","doi-asserted-by":"publisher","first-page":"95","DOI":"10.3233\/JPD-160911","volume":"7","author":"C Cattaneo","year":"2017","unstructured":"Cattaneo C, Barone P, Bonizzoni E, Sardina M. Effects of safinamide on pain in fluctuating Parkinson\u2019s disease patients: a post-hoc analysis. J Parkinsons Dis. 2017;7(1):95\u2013101.","journal-title":"J Parkinsons Dis"},{"issue":"4","key":"2736_CR16","doi-asserted-by":"publisher","first-page":"629","DOI":"10.3233\/JPD-171143","volume":"7","author":"C Cattaneo","year":"2017","unstructured":"Cattaneo C, M\u00fcller T, Bonizzoni E, et al. Long-term effects of safinamide on mood fluctuations in Parkinson\u2019s disease. J Parkinsons Dis. 2017;7(4):629\u201334.","journal-title":"J Parkinsons Dis"},{"issue":"4","key":"2736_CR17","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1007\/s12325-018-0687-z","volume":"35","author":"C Cattaneo","year":"2018","unstructured":"Cattaneo C, Kulisevsky J, Tubazio V, Castellani P. Long-term efficacy of safinamide on Parkinson\u2019s disease chronic pain. Adv Ther. 2018;35(4):515\u201322.","journal-title":"Adv Ther"},{"key":"2736_CR18","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.756304","volume":"12","author":"MT Pellecchia","year":"2021","unstructured":"Pellecchia MT, Picillo M, Russillo MC, et al. Efficacy of safinamide and gender differences during routine clinical practice. Front Neurol. 2021;12:756304. https:\/\/doi.org\/10.3389\/fneur.2021.756304.","journal-title":"Front Neurol"},{"issue":"2","key":"2736_CR19","doi-asserted-by":"publisher","first-page":"180","DOI":"10.14802\/jmd.22196","volume":"16","author":"R Bhidayasiri","year":"2023","unstructured":"Bhidayasiri R, Ishida T, Kamei T, et al. Safinamide as an adjunct to levodopa in Asian and Caucasian patients with Parkinson\u2019s disease and motor fluctuations: a post-hoc analysis of the SETTLE study. J Mov Disord. 2023;16(2):180\u201390.","journal-title":"J Mov Disord"},{"issue":"5","key":"2736_CR20","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.251","volume":"4","author":"L Loprete","year":"2016","unstructured":"Loprete L, Leuratti C, Cattaneo C, Thapar MM, Farrell C, Sardina M. Population pharmacokinetic and pharmacodynamic analyses of safinamide in subjects with Parkinson\u2019s disease. Pharma Res Per. 2016;4(5):e00251. https:\/\/doi.org\/10.1002\/prp2.251.","journal-title":"Pharma Res Per"},{"key":"2736_CR21","volume-title":"Parkinson\u2019s disease: national clinical guideline for diagnosis and management in primary and secondary care","author":"National Collaborating Centre for Chronic Conditions","year":"2006","unstructured":"National Collaborating Centre for Chronic Conditions. Parkinson\u2019s disease: national clinical guideline for diagnosis and management in primary and secondary care. London: Royal College of Physicians; 2006."},{"issue":"5","key":"2736_CR22","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1212\/WNL.17.5.427","volume":"17","author":"M Hoehn","year":"1967","unstructured":"Hoehn M, Yahr M. Parkinsonism: onset, progression and mortality. Neurology. 1967;17(5):427\u201342.","journal-title":"Neurology"},{"key":"2736_CR23","first-page":"153","volume-title":"Recent developments in Parkinson\u2019s disease","author":"S Fahn","year":"1987","unstructured":"Fahn S, Elton R, Members of the UPDRS Development Committee. The unified Parkinson\u2019s disease rating scale. In: Fahn S, Marsden CD, Calne DB, Goldstein M, editors. Recent developments in Parkinson\u2019s disease, vol. 2. Florham Park: McMellam Health Care Information; 1987. p. 153\u201363."},{"key":"2736_CR24","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1007\/BF02260863","volume":"4","author":"V Peto","year":"1995","unstructured":"Peto V, Jenkinson C, Fitzpatrick R, Greenhall R. The development and validation of a short measure of functioning and well-being for individuals with Parkinson\u2019s disease. Qual Lif Res. 1995;4:241\u20138.","journal-title":"Qual Lif Res"},{"key":"2736_CR25","unstructured":"World Health Organization-Drug Dictionary (WHO-DD), Uppsala Monitoring Centre; 2020."},{"key":"2736_CR26","unstructured":"Medical Dictionary for Regulatory Activities (MedDRA) version 23.1, September 2020."},{"key":"2736_CR27","unstructured":"ICH Topic E10. Note for guidance on choice of control groups in clinical trials. CPMP\/ICH\/364\/96 January 2001."},{"issue":"1","key":"2736_CR28","doi-asserted-by":"publisher","first-page":"31","DOI":"10.3233\/JPD-191763","volume":"10","author":"A Ben-Joseph","year":"2020","unstructured":"Ben-Joseph A, Marshall CR, Lees AJ, Noyce A. Ethnic variation in the manifestation of Parkinson\u2019s disease: a narrative review. J Parkinsons Dis. 2020;10(1):31\u201345.","journal-title":"J Parkinsons Dis"},{"issue":"1","key":"2736_CR29","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1001\/archneurol.2009.295","volume":"67","author":"LM Shulman","year":"2010","unstructured":"Shulman LM, Gruber-Baldini AL, Anderson KE, et al. The clinically important difference on the unified Parkinson\u2019s disease rating scale. Arch Neurol. 2010;67(1):64\u201370.","journal-title":"Arch Neurol"},{"key":"2736_CR30","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/BF02740748","volume":"12","author":"F Blandini","year":"1996","unstructured":"Blandini F, Porter RH, Greenamyre JT. Glutamate and Parkinson\u2019s disease. Mol Neurobiol. 1996;12:73\u201394.","journal-title":"Mol Neurobiol"},{"key":"2736_CR31","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.jocn.2021.05.056","volume":"90","author":"J Pagonabarraga","year":"2021","unstructured":"Pagonabarraga J, Tinazzi M, Caccia C, Jost WH. The role of glutamatergic neurotransmission in the motor and non-motor symptoms in Parkinson\u2019s disease: clinical cases and a review of the literature. J Clin Neurosci. 2021;90:178\u201383.","journal-title":"J Clin Neurosci"},{"key":"2736_CR32","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2022.86652","volume":"13","author":"J Kulisevsky","year":"2022","unstructured":"Kulisevsky J, Martinez-Horta S, Campolongo A, et al. A randomized clinical trial to evaluate the effects of safinamide on apathetic non-demented patients with Parkinson\u2019s disease. Front Neurol. 2022;13:866502. https:\/\/doi.org\/10.3389\/fneur.2022.86652.","journal-title":"Front Neurol"},{"issue":"1","key":"2736_CR33","doi-asserted-by":"publisher","first-page":"165","DOI":"10.3233\/JPD-150700","volume":"6","author":"C Cattaneo","year":"2016","unstructured":"Cattaneo C, Sardina M, Bonizzoni E. Safinamide as add-on therapy to levodopa in mid- to late-stage Parkinson\u2019s disease fluctuating patients: post-hoc analyses of studies 016 and SETTLE. J Parkinsons Dis. 2016;6(1):165\u201373.","journal-title":"J Parkinsons Dis"},{"key":"2736_CR34","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1001\/archneur.62.2.241","volume":"62","author":"Parkinson Study Group","year":"2005","unstructured":"Parkinson Study Group. A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson\u2019s disease and motor fluctuations: the PRESTO study. Arch Neurol. 2005;62:241\u20138.","journal-title":"Arch Neurol"},{"key":"2736_CR35","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s40035-018-0119-7","volume":"7","author":"Z Zhang","year":"2018","unstructured":"Zhang Z, Shao M, Chen S, et al. Adjunct rasagiline to treat Parkinson\u2019s disease with motor fluctuations; a randomized, double-blind study in China. Transl Neurodegener. 2018;7:14. https:\/\/doi.org\/10.1186\/s40035-018-0119-7.","journal-title":"Transl Neurodegener"},{"issue":"2","key":"2736_CR36","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/S1474-4422(15)00336-1","volume":"15","author":"JJ Ferreira","year":"2016","unstructured":"Ferreira JJ, Lees A, Rocha JF, et al. Opicapone as an adjunct to levodopa in patients with Parkinson\u2019s disease and end-of-dose motor fluctuations: a randomized, double-blind, controlled trial. Lancet Neurol. 2016;15(2):154\u201365.","journal-title":"Lancet Neurol"},{"issue":"2","key":"2736_CR37","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1001\/jamaneurol.2016.4703","volume":"74","author":"AJ Lees","year":"2017","unstructured":"Lees AJ, Ferreira J, Rascol O, et al. Opicapone as adjunct to levodopa therapy in patients with Parkinson\u2019s disease and motor fluctuations: a randomized clinical trial. JAMA Neurol. 2017;74(2):197\u2013206.","journal-title":"JAMA Neurol"},{"issue":"3","key":"2736_CR38","doi-asserted-by":"publisher","first-page":"475","DOI":"10.3233\/JPD-150569","volume":"5","author":"C Cattaneo","year":"2015","unstructured":"Cattaneo C, La Ferla R, Bonizzoni E, Sardina M. Long-term effects of safinamide on dyskinesia in mid- to late-stage Parkinson\u2019s disease: a post-hoc analysis. J Parkinsons Dis. 2015;5(3):475\u201381.","journal-title":"J Parkinsons Dis"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-023-02736-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-023-02736-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-023-02736-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,4]],"date-time":"2024-02-04T05:16:05Z","timestamp":1707023765000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-023-02736-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,9]]},"references-count":38,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["2736"],"URL":"https:\/\/doi.org\/10.1007\/s12325-023-02736-2","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"type":"print","value":"0741-238X"},{"type":"electronic","value":"1865-8652"}],"subject":[],"published":{"date-parts":[[2023,12,9]]},"assertion":[{"value":"2 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 December 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Carlo Cattaneo is an employee of Zambon SpA; Jaime Kulisevsky has received compensation for consultancy and speaker related activities from Zambon SpA.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article is based on the data of the previously conducted studies SUCCESS and XINDI that have been approved in all countries by ethical national committees and national health authorities and were performed according to the guidelines of the Declaration of Helsinki. The authors received permission to access the data. No new studies with human participants have been performed for this publication. Written informed and privacy consents to participate in the studies SUCCESS and XINDI, collect, analyze, and report anonymized and aggregated data were obtained from all patients.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}